Gland Pharma Limited
GLAND
Rang in aandelen
#3303
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Aandeelprijs
$32.32
Marktkapitalisatie
$5.33B
Verandering (1 dag)
-3.01%
Verandering (1 jaar)
47.99%
Land
IN
Handel Gland Pharma Limited (GLAND)
Categorie
Healthcare
Winst voor Gland Pharma Limited (GLAND)
Winst in Jun 2026 TTM: $175.12M
Volgens de meest recente financiële verslagen van Gland Pharma Limited bedraagt de huidige winst van het bedrijf $175.12M. In 2024 behaalde het bedrijf een winst van $135.82M, een stijging ten opzichte van de winst van 2023, die $128.32M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Gland Pharma Limited van 2017 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $175.12M | 40.94% |
| 2025 | $124.25M | -8.52% |
| 2024 | $135.82M | 5.84% |
| 2023 | $128.32M | -39.82% |
| 2022 | $213.22M | 16.94% |
| 2021 | $182.34M | 38.35% |
| 2020 | $131.79M | 33.35% |
| 2019 | $98.83M | 28.32% |
| 2018 | $77.02M | -13.59% |
| 2017 | $89.13M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 907.63% |
IN
|
